The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.
 
Eunice Lee Kwak
Research Funding - Amgen
 
Patricia LoRusso
No Relationships to Disclose
 
Omid Hamid
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Amgen
 
Filip Janku
No Relationships to Disclose
 
Muaiad Kittaneh
No Relationships to Disclose
 
Daniel Virgil Thomas Catenacci
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen
 
Emily Chan
Consulting or Advisory Role - Amgen; Lilly
Research Funding - Aduro Biotech (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Dekkun Corporation (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Lilly; Regeneron
Research Funding - NCCN; NCI; Oncolytics
Expert Testimony - Helsinn Therapeutics
Other Relationship - Exelixis; Polaris
 
Benny Amore
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Yuying C. Hwang
Employment - Amgen; Amgen (I)
Stock and Other Ownership Interests - Amgen; Amgen (I)
 
Rui Tang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Gataree Ngarmchamnanrith
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
David S. Hong
Research Funding - Amgen